Monoclonal Antibody treatment
SARS-CoV-2 monoclonal antibodies (SMA) have been approved by the FDA for Emergency Use Authorization (EUA) for high-risk outpatients with symptomatic COVID-19 infection. There are 2 monoclonal antibody treatments available.
These medications are administrated via infusion and the patient should receive one or the other.
EUA Fact Sheets for Healthcare Providers
EUA Fact Sheets for Patients, Parents and Caregivers
Please review the emergency use authorization (EUA) with the patient to confirm the patient wants the therapy prior to patient submission:
Please use the Life Sustaining Business List to confirm if patient is classified as an "essential worker."
- Patients should be informed of their positive test result and have potential interest in receiving the monoclonal medication confirmed prior to referral.
- Patients will be allocated the medications via weighted lottery based on patient eligibility and availability of the medication and infusion resources.
- Patients and referring providers of eligible patients selected to receive the medication will be contacted within 2 business days of referral.
Treatment request forms
Please download and print the relevant document to register the patient and fax to the number provided on the document. Please print and complete the document in its entirety in order to ensure the patient's information is able to be transcribed.